0 references
<span>Comparison outcome&nbsp;of&nbsp;transarterial&nbsp;chemoembolization&nbsp;combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib as first-line therapy for advanced hepatocellular carcinoma</span>
SSRN Electronic Journal2024
Ningning Zhang, Yawei Du, Yuexi Yu, Qiang Wu, Wei Bai, Wei Zhang, Shuwen Zhang, Wenwen Zhu, Yu Hao, Xuanchen Liu, Ming Luo, Huiru Liu, Kaipeng Liu, Yiyan Zhang, Yiming Huo, Guohong Han, Haipeng Yu, Jihui Hao, Wei‐Yang Lu
Related Papers
- → Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma(2021)38 cited
- → Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma(2020)12 cited
- → A useful case of tumor resection and monitoring the blood concentration at lenvatinib therapy for multiple hepatocellular carcinoma(2021)2 cited
- → Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib(2022)1 cited
- → Associations between plasma concentrations of lenvatinib and angiopoietin and clinical responses to lenvatinib therapy in Japanese patients with thyroid cancer(2021)